nach oben

Die Ophthalmologie

Erschienen in:

01.04.2013 | Übersichten

Effekte von Resveratrol am Augenhintergrund

Ein Überblick

verfasst von: Dr. A.F. Alex, N. Eter

Erschienen in: Die Ophthalmologie | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Zusammenfassung

Resveratrol ist ein Polyphenol mit diversen Eigenschaften. Onkologische Untersuchungen zeigten eine hervorragende antikarzinogene Wirkung. Aufgrund zahlreicher Überschneidungen der tumorvermittelnden Signale mit solchen in neovaskulären und proliferativen Netzhauterkrankungen sollen in dieser Übersicht allgemeine Signalwege und Ergebnisse der Anwendung von Resveratrol am Augenhintergrund in vitro und in vivo dargestellt werden. Resveratrol ist in Zellkulturmodellen und Tiermodellen bereits gut untersucht. Ophthalmologische In-vitro- und In-vivo-Studien zeigen ein breites Wirkspektrum ohne toxische Nebenwirkungen. Vor allem antiproliferative und immunmodulatorische Effekte wurden nachgewiesen. Einigkeit besteht über ein zentrales Zielprotein von Resveratrol, das NF-κB. Klinische Untersuchungen müssen folgen, um diese in Zellkultur- und Tiermodellen bestimmten Effekte zu verifizieren. Der genaue Wirkmechanismus von Resveratrol ist noch nicht bekannt und scheint zwischen Zellen, Geweben und dem pathophysiologischen Milieu zu variieren.

Alex AF, Spitznas M, Tittel AP et al (2010) Inhibitory effect of epigallocatechin gallate (EGCG), resveratrol, and curcumin on proliferation of human retinal pigment epithelial cells in vitro. Curr Eye Res 35:1021–1033PubMedCrossRef

Almeida L, Vaz-Da-Silva M, Falcao A et al (2009) Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res 53(Suppl 1):S7–15PubMedCrossRef

Ambati J, Ambati BK, Yoo SH et al (2003) Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 48:257–293PubMedCrossRef

Ambati J, Anand A, Fernandez S et al (2003) An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice. Nat Med 9:1390–1397PubMedCrossRef

Anekonda TS, Adamus G (2008) Resveratrol prevents antibody-induced apoptotic death of retinal cells through upregulation of Sirt1 and Ku70. BMC Res Notes 1:122PubMedCrossRef

Arunachalam G, Yao H, Sundar IK et al (2010) SIRT1 regulates oxidant- and cigarette smoke-induced eNOS acetylation in endothelial cells: role of resveratrol. Biochem Biophys Res Commun 393:66–72PubMedCrossRef

Bass TM, Weinkove D, Houthoofd K et al (2007) Effects of resveratrol on lifespan in Drosophila melanogaster and Caenorhabditis elegans. Mech Ageing Dev 128:546–552PubMedCrossRef

Baur JA, Pearson KJ, Price NL et al (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444:337–342PubMedCrossRef

Baur JA, Sinclair DA (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5:493–506PubMedCrossRef

10.

Belleri M, Ribatti D, Savio M et al (2008) alphavbeta3 Integrin-dependent antiangiogenic activity of resveratrol stereoisomers. Mol Cancer Ther 7:3761–3770PubMedCrossRef

11.

Benitez DA, Hermoso MA, Pozo-Guisado E et al (2009) Regulation of cell survival by resveratrol involves inhibition of NF kappa B-regulated gene expression in prostate cancer cells. Prostate 69:1045–1054PubMedCrossRef

12.

Blasi E, Barluzzi R, Bocchini V et al (1990) Immortalization of murine microglial cells by a v-raf/v-myc carrying retrovirus. J Neuroimmunol 27:229–237PubMedCrossRef

13.

Bonastre J, Le Pen C, Anderson P et al (2002) The epidemiology, economics and quality of life burden of age-related macular degeneration in France, Germany, Italy and the United Kingdom. Eur J Health Econ 3:94–102PubMedCrossRef

14.

Boocock DJ, Faust GE, Patel KR et al (2007) Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 16:1246–1252PubMedCrossRef

15.

Brown VA, Patel KR, Viskaduraki M et al (2010) Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res 70:9003–9011PubMedCrossRef

16.

Cao L, Liu H, Lam DS et al (2010) In vitro screening for angiostatic potential of herbal chemicals. Invest Ophthalmol Vis Sci 51:6658–6664PubMedCrossRef

17.

Choi DK, Koppula S, Suk K (2011) Inhibitors of microglial neurotoxicity: focus on natural products. Molecules 16:1021–1043PubMedCrossRef

18.

Csaki C, Mobasheri A, Shakibaei M (2009) Synergistic chondroprotective effects of curcumin and resveratrol in human articular chondrocytes: inhibition of IL-1beta-induced NF-kappaB-mediated inflammation and apoptosis. Arthritis Res Ther 11:R165PubMedCrossRef

19.

Delmas D, Jannin B, Latruffe N (2005) Resveratrol: preventing properties against vascular alterations and ageing. Mol Nutr Food Res 49:377–395PubMedCrossRef

20.

Delmas D, Lancon A, Colin D et al (2006) Resveratrol as a chemopreventive agent: a promising molecule for fighting cancer. Curr Drug Targets 7:423–442PubMedCrossRef

21.

Dore S (2005) Unique properties of polyphenol stilbenes in the brain: more than direct antioxidant actions; gene/protein regulatory activity. Neurosignals 14:61–70PubMedCrossRef

22.

Dugas B, Charbonnier S, Baarine M et al (2010) Effects of oxysterols on cell viability, inflammatory cytokines, VEGF, and reactive oxygen species production on human retinal cells: cytoprotective effects and prevention of VEGF secretion by resveratrol. Eur J Nutr 49:435–446PubMedCrossRef

23.

Eter N, Engel DR, Meyer L et al (2008) In vivo visualization of dendritic cells, macrophages, and microglial cells responding to laser-induced damage in the fundus of the eye. Invest Ophthalmol Vis Sci 49:3649–3658PubMedCrossRef

24.

Fukuda S, Kaga S, Zhan L et al (2006) Resveratrol ameliorates myocardial damage by inducing vascular endothelial growth factor-angiogenesis and tyrosine kinase receptor Flk-1. Cell Biochem Biophys 44:43–49PubMedCrossRef

25.

Goldberg DM, Yan J, Soleas GJ (2003) Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem 36:79–87PubMedCrossRef

26.

Guarente L (2006) Sirtuins as potential targets for metabolic syndrome. Nature 444:868–874PubMedCrossRef

27.

Han YS, Bastianetto S, Dumont Y et al (2006) Specific plasma membrane binding sites for polyphenols, including resveratrol, in the rat brain. J Pharmacol Exp Ther 318:238–245PubMedCrossRef

28.

Howitz KT, Bitterman KJ, Cohen HY et al (2003) Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425:191–196PubMedCrossRef

29.

Hua J, Guerin KI, Chen J et al (2011) Resveratrol inhibits pathologic retinal neovascularization in Vldlr(–/–) mice. Invest Ophthalmol Vis Sci 52:2809–2816PubMedCrossRef

30.

Jang M, Cai L, Udeani GO et al (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275:218–220PubMedCrossRef

31.

Kim WT, Suh ES (2010) Retinal protective effects of resveratrol via modulation of nitric oxide synthase on oxygen-induced retinopathy. Korean J Ophthalmol 24:108–118PubMedCrossRef

32.

Kim YH, Kim YS, Kang SS et al (2010) Resveratrol inhibits neuronal apoptosis and elevated Ca2+ /calmodulin-dependent protein kinase II activity in diabetic mouse retina. Diabetes 59:1825–1835PubMedCrossRef

33.

Kim YH, Kim YS, Roh GS et al (2012) Resveratrol blocks diabetes-induced early vascular lesions and vascular endothelial growth factor induction in mouse retinas. Acta Ophthalmol 90:e31–37PubMedCrossRef

34.

Kimura Y, Okuda H, Arichi S (1985) Effects of stilbenes on arachidonate metabolism in leukocytes. Biochim Biophys Acta 834:275–278PubMedCrossRef

35.

King RE, Kent KD, Bomser JA (2005) Resveratrol reduces oxidation and proliferation of human retinal pigment epithelial cells via extracellular signal-regulated kinase inhibition. Chem Biol Interact 151:143–149PubMedCrossRef

36.

Kubota S, Kurihara T, Ebinuma M et al (2010) Resveratrol prevents light-induced retinal degeneration via suppressing activator protein-1 activation. Am J Pathol 177:1725–1731PubMedCrossRef

37.

Kubota S, Kurihara T, Mochimaru H et al (2009) Prevention of ocular inflammation in endotoxin-induced uveitis with resveratrol by inhibiting oxidative damage and nuclear factor-kappaB activation. Invest Ophthalmol Vis Sci 50:3512–3519PubMedCrossRef

38.

Kubota S, Ozawa Y, Kurihara T et al (2011) Roles of AMP-activated protein kinase in diabetes-induced retinal inflammation. Invest Ophthalmol Vis Sci 52:9142–9148PubMedCrossRef

39.

Lancon A, Delmas D, Osman H et al (2004) Human hepatic cell uptake of resveratrol: involvement of both passive diffusion and carrier-mediated process. Biochem Biophys Res Commun 316:1132–1137PubMedCrossRef

40.

Langcake P, Pryce RJ (1977) A new class of phytoalexins from grapevines. Experientia 33:151–152PubMedCrossRef

41.

Li C, Wang L, Huang K et al (2012) Endoplasmic reticulum stress in retinal vascular degeneration: protective role of resveratrol. Invest Ophthalmol Vis Sci 53:3241–3249PubMedCrossRef

42.

Li W, Jiang D (2012) Effect of resveratrol on bcl-2 and VEGF expression in oxygen-induced retinopathy of prematurity. J Pediatr Ophthalmol Strabismus 49:230–235PubMedCrossRef

43.

Lopez PF, Sippy BD, Lambert HM et al (1996) Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 37:855–868PubMed

44.

Losso JN, Truax RE, Richard G (2010) trans-resveratrol inhibits hyperglycemia-induced inflammation and connexin downregulation in retinal pigment epithelial cells. J Agric Food Chem 58:8246–8252PubMedCrossRef

45.

Lu X, Ma L, Ruan L et al (2010) Resveratrol differentially modulates inflammatory responses of microglia and astrocytes. J Neuroinflammation 7:46PubMedCrossRef

46.

Maccarrone M, Lorenzon T, Guerrieri P et al (1999) Resveratrol prevents apoptosis in K562 cells by inhibiting lipoxygenase and cyclooxygenase activity. Eur J Biochem 265:27–34PubMedCrossRef

47.

Maier-Salamon A, Hagenauer B, Wirth M et al (2006) Increased transport of resveratrol across monolayers of the human intestinal Caco-2 cells is mediated by inhibition and saturation of metabolites. Pharm Res 23:2107–2115PubMedCrossRef

48.

Meng X, Maliakal P, Lu H et al (2004) Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. J Agric Food Chem 52:935–942PubMedCrossRef

49.

Moon SO, Kim W, Sung MJ et al (2006) Resveratrol suppresses tumor necrosis factor-alpha-induced fractalkine expression in endothelial cells. Mol Pharmacol 70:112–119PubMed

50.

Nagaoka T, Hein TW, Yoshida A et al (2007) Resveratrol, a component of red wine, elicits dilation of isolated porcine retinal arterioles: role of nitric oxide and potassium channels. Invest Ophthalmol Vis Sci 48:4232–4239PubMedCrossRef

51.

Parekh P, Motiwale L, Naik N et al (2011) Downregulation of cyclin D1 is associated with decreased levels of p38 MAP kinases, Akt/PKB and Pak1 during chemopreventive effects of resveratrol in liver cancer cells. Exp Toxicol Pathol 63:167–173PubMedCrossRef

52.

Park ES, Lim Y, Hong JT et al (2010) Pterostilbene, a natural dimethylated analog of resveratrol, inhibits rat aortic vascular smooth muscle cell proliferation by blocking Akt-dependent pathway. Vascul Pharmacol 53:61–67PubMedCrossRef

53.

Patel KR, Brown VA, Jones DJ et al (2010) Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res 70:7392–7399PubMedCrossRef

54.

Pintea A, Rugina D, Pop R et al (2011) Antioxidant effect of trans-resveratrol in cultured human retinal pigment epithelial cells. J Ocul Pharmacol Ther 27:315–321PubMedCrossRef

55.

Renaud S, De Lorgeril M (1993) The French paradox: dietary factors and cigarette smoking-related health risks. Ann N Y Acad Sci 686:299–309PubMedCrossRef

56.

Renaud S, De Lorgeril M (1992) Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 339:1523–1526PubMedCrossRef

57.

Sakurai E, Anand A, Ambati BK et al (2003) Macrophage depletion inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 44:3578–3585PubMedCrossRef

58.

Sheu SJ, Liu NC, Chen JL (2010) Resveratrol protects human retinal pigment epithelial cells from acrolein-induced damage. J Ocul Pharmacol Ther 26:231–236PubMedCrossRef

59.

Sheu SJ, Wu TT (2009) Resveratrol protects against ultraviolet A-mediated inhibition of the phagocytic function of human retinal pigment epithelial cells via large-conductance calcium-activated potassium channels. Kaohsiung J Med Sci 25:381–388PubMedCrossRef

60.

Simao F, Pagnussat AS, Seo JH et al (2012) Pro-angiogenic effects of resveratrol in brain endothelial cells: nitric oxide-mediated regulation of vascular endothelial growth factor and metalloproteinases. J Cereb Blood Flow Metab 32:884–895PubMedCrossRef

61.

Sparrow JR, Vollmer-Snarr HR, Zhou J et al (2003) A2E-epoxides damage DNA in retinal pigment epithelial cells. Vitamin E and other antioxidants inhibit A2E-epoxide formation. J Biol Chem 278:18207–18213PubMedCrossRef

62.

Stewart JR, O’brian CA (2004) Resveratrol antagonizes EGFR-dependent Erk1/2 activation in human androgen-independent prostate cancer cells with associated isozyme-selective PKC alpha inhibition. Invest New Drugs 22:107–117PubMedCrossRef

63.

Stewart JR, Ward NE, Ioannides CG et al (1999) Resveratrol preferentially inhibits protein kinase C-catalyzed phosphorylation of a cofactor-independent, arginine-rich protein substrate by a novel mechanism. Biochemistry 38:13244–13251PubMedCrossRef

64.

Subramanian L, Youssef S, Bhattacharya S et al (2010) Resveratrol: challenges in translation to the clinic: a critical discussion. Clin Cancer Res 16:5942–5948PubMedCrossRef

65.

Szewczuk LM, Forti L, Stivala LA et al (2004) Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2: a mechanistic approach to the design of COX-1 selective agents. J Biol Chem 279:22727–22737PubMedCrossRef

66.

Vitrac X, Desmouliere A, Brouillaud B et al (2003) Distribution of [14C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration. Life Sci 72:2219–2233PubMedCrossRef

67.

Walle T, Hsieh F, Delegge MH et al (2004) High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 32:1377–1382PubMedCrossRef

68.

Wang L, Clark ME, Crossman DK et al (2010) Abundant lipid and protein components of drusen. PLoS One 5:e10329PubMedCrossRef

69.

Wang Z, Hsieh TC, Zhang Z et al (2004) Identification and purification of resveratrol targeting proteins using immobilized resveratrol affinity chromatography. Biochem Biophys Res Commun 323:743–749PubMedCrossRef

70.

Wenzel E, Soldo T, Erbersdobler H et al (2005) Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. Mol Nutr Food Res 49:482–494PubMedCrossRef

71.

Williams LD, Burdock GA, Edwards JA et al (2009) Safety studies conducted on high-purity trans-resveratrol in experimental animals. Food Chem Toxicol 47:2170–2182PubMedCrossRef

72.

Yun JM, Chien A, Jialal I et al (2012) Resveratrol up-regulates SIRT1 and inhibits cellular oxidative stress in the diabetic milieu: mechanistic insights. J Nutr Biochem 23:699–705PubMedCrossRef

73.

Zhang F, Liu J, Shi JS (2010) Anti-inflammatory activities of resveratrol in the brain: role of resveratrol in microglial activation. Eur J Pharmacol 636:1–7PubMedCrossRef

74.

Zhang F, Wang H, Wu Q et al (2012) Resveratrol protects cortical neurons against microglia-mediated neuroinflammation. Phytother Res [Epub ahead of print]

75.

Zhong LM, Zong Y, Sun L et al (2012) Resveratrol inhibits inflammatory responses via the mammalian target of rapamycin signaling pathway in cultured LPS-stimulated microglial cells. PLoS One 7:e32195PubMedCrossRef

76.

Takaoka MJ (1940) Of the phenolic substances of white hellebore (Veratrum grandiflorum Loes. fil.). J Faculty Sci Hokkaido Imperial University 3:1–16

Titel: Effekte von Resveratrol am Augenhintergrund
Ein Überblick
verfasst von: Dr. A.F. Alex
N. Eter
Publikationsdatum: 01.04.2013
Verlag: Springer-Verlag
Erschienen in: Die Ophthalmologie / Ausgabe 4/2013
Print ISSN: 2731-720X
Elektronische ISSN: 2731-7218
DOI: https://doi.org/10.1007/s00347-012-2744-3

Neu im Fachgebiet Augenheilkunde

08.04.2024 | Therapieverfahren in der Augenheilkunde | CME

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Effekte von Resveratrol am Augenhintergrund

Ein Überblick

Zusammenfassung

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2013

Behandlungsfehler in der Augenheilkunde

Aktuelle Glaukomchirurgie

Kombinierte Katarakt-Glaukom-Chirurgie

Kataraktchirurgie beim Glaukom

Erratum zu: Rolle des Energiestoffwechsels im retinalen Pigmentepithel

Ätiologie und Pathogenese der altersabhängigen Makuladegeneration

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde